Ibandronate (Boniva and others)

How Medicare covers it

Part D (monthly tablets taken at home). Part A during a covered inpatient stay. The clinician-administered injection form also has a Part B basis (see Part B status).

What it treats

Osteoporosis in postmenopausal women — both treating osteoporosis that is already present and preventing it. The label states the tablets increase bone mineral density and reduce the incidence of spine (vertebral) fractures.

What it is for, in depth

Ibandronate is a bisphosphonate prescribed for postmenopausal women to treat osteoporosis that is already present and to prevent it in women at risk; in the label's trials it increased bone mineral density and reduced the number of new vertebral (spine) fractures. The packaged product for this page is the 150 mg tablet taken once a month, on the same date each month, which suits people who prefer a monthly tablet over a daily or weekly one. The strict dosing routine — plain water only, empty stomach, staying upright for 60 minutes — exists to get the drug absorbed and to protect the esophagus. The label notes the best length of treatment has not been determined: the safety and effectiveness data cover three years, the need for continued therapy should be re-checked periodically, and people at low risk of fracture should be considered for stopping after 3 to 5 years, with fracture risk re-checked after stopping. A separate ibandronate injection form, given into a vein by a clinician every 3 months, also exists, but this entry is based on the oral tablet label, which covers the tablet only.

How it works

Ibandronate is a bisphosphonate. It attaches to hydroxyapatite, part of the mineral that makes up bone, and blocks the osteoclast cells that break bone down. This slows bone loss and turnover, and in postmenopausal women it lowers the raised rate of bone turnover so that, on average, bone mass increases.

How it is taken

One 150 mg tablet taken once a month, on the same date each month. Take it first thing, at least 60 minutes before the first food, drink (other than water), or other medicine of the day. Swallow the tablet whole — do not chew or suck it — with a full glass (6 to 8 ounces) of plain water only (not mineral water) while standing or sitting upright. Do not lie down for at least 60 minutes after taking it, and do not eat, drink anything except plain water, or take other medicines for at least 60 minutes. Take calcium and vitamin D supplements if you do not get enough from your diet, but not within 60 minutes of the tablet. If you miss the monthly dose and your next scheduled day is more than 7 days away, take one tablet the next morning after you remember; if the next scheduled day is only 1 to 7 days away, wait and take the tablet on the next month's scheduled day. Never take two 150 mg tablets in the same week.

Common side effects

The most common adverse reactions (more than 5%) in the label are back pain, indigestion (dyspepsia), pain in an arm or leg, diarrhea, headache, and muscle pain (myalgia). In the two-year monthly-dosing trial, reactions in people taking the 150 mg tablet once a month included abdominal pain (7.8%), indigestion (5.6%), joint pain (5.6%), nausea (5.1%), diarrhea (5.1%), back pain (4.5%), constipation (4.0%), flu (4.0%), pain in an arm or leg (4.0%), headache (3.3%), and flu-like illness (3.3%). Flu-like acute phase symptoms within 3 days of the monthly dose occurred in 9% of the monthly group over the two years. In the daily-dosing studies, indigestion was 12%, back pain 14%, diarrhea 7%, and headache 7% on ibandronate.

Serious warnings

Oral bisphosphonates can severely irritate the upper digestive tract: inflammation, ulcers, and erosions of the esophagus have been reported, occasionally with bleeding and rarely followed by narrowing (stricture) or perforation, and some cases needed hospital care. Stop the drug and seek medical attention for trouble swallowing, pain when swallowing, pain behind the breastbone, or new or worsening heartburn. Low blood calcium (hypocalcemia) has been reported and may worsen during treatment; it must be corrected before starting. Severe and occasionally disabling bone, joint, or muscle pain has been reported, starting anywhere from one day to several months after starting. Osteonecrosis of the jaw (death of jaw bone) has been reported, generally with tooth extraction or local infection and delayed healing, and the risk rises with longer use. Unusual (atypical) fractures of the thigh bone and other bones, sometimes with little or no injury, have been reported; new thigh or groin pain should be checked to rule out a femur fracture.

Who should be careful

Ibandronate tablets must not be used by people with abnormalities of the esophagus that delay its emptying, such as stricture or achalasia; by people who cannot stand or sit upright for at least 60 minutes; by people with low blood calcium (hypocalcemia), which must be treated first; or by anyone allergic to ibandronate or its ingredients — cases of anaphylaxis have been reported. Caution is needed in people with active upper digestive problems such as Barrett's esophagus, trouble swallowing, other esophageal diseases, gastritis, duodenitis, or ulcers. It is not recommended in severe kidney impairment (creatinine clearance under 30 mL/min). People planning invasive dental work, and people with risk factors for jaw osteonecrosis such as cancer, chemotherapy or corticosteroid treatment, poor oral hygiene, or existing dental disease, should discuss it with their doctor and dentist before and during treatment.

Major interactions

Products containing calcium and other multivalent cations — such as calcium supplements, antacids, and supplements or vitamins containing aluminum, magnesium, or iron — interfere with the absorption of ibandronate, so it must be taken at least 60 minutes before any of them, and no other oral medicine should be taken for at least 60 minutes after the dose. Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) can irritate the stomach and gut, as can ibandronate, so use them together with caution. The H2 blocker ranitidine raised ibandronate levels in the blood by about 20%, which the label says was not considered clinically important.

Cost and saving notes

Ibandronate is sold as a generic, and generic ibandronate 150 mg tablets are widely available, which usually keeps the monthly tablet on a lower Part D tier than the brand name Boniva. Ask your pharmacist to confirm you are getting the generic, and ask your plan for a tier exception if the tablet is placed on a higher tier. If you have limited income, Extra Help (the Part D Low Income Subsidy) can lower premiums and copays. In 2027, Part D out-of-pocket drug spending is capped at $2,400 for the year, and the Medicare Prescription Payment Plan lets you spread out-of-pocket costs into monthly payments. Always confirm the current tier and price with your plan or pharmacist, because formularies change.

Why it is in its tier

Ibandronate (Boniva and others) sits on Tier 2 in 68.53% of the plans that list it (3671 of 5357 listing plans). Tier 2 is the generic tier — low copays. The data-visible drivers: It is a generic product, and the CMS dashboard puts its average Part D spending at about $97.72 per beneficiary for 2024 — a relatively low-cost drug, which matches where plans place it. It is listed by 97.49% of Part D plans. The tier shown is the most common one; individual plans vary.

Sources

• IBANDRONATE SODIUM TABLET, FILM COATED [MACLEODS PHARMACEUTICALS LIMITED] — DailyMed
• MedlinePlus — National Library of Medicine
• MedlinePlus — Ibandronate

What official patient guides say

Ibandronate comes as a tablet to take by mouth. The 150-mg tablet is taken once a month in the morning on an empty stomach, on the same date each month. Take it just after you get out of bed, before you eat or drink anything — never at bedtime. Swallow it whole with a full glass (6 to 8 ounces) of plain water only; never take it with tea, coffee, juice, milk, mineral water, or sparkling water, and do not split, chew, crush, or suck on it. For at least 60 minutes afterward, do not eat, drink, or take other medications, including vitamins or antacids, and do not lie down — sit or stand upright. If you forget the monthly tablet and your next scheduled day is more than seven days away, take it the morning after you remember; if it is seven or fewer days away, skip it. Never take two 150-mg tablets within one week. Store ibandronate at room temperature away from heat and moisture, out of reach of children, and eat calcium- and vitamin D-rich foods.

Source: MedlinePlus — Ibandronate

Part D formulary coverage

Source: CMS Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files — Monthly file 2026-10-15 (plan year 2027), file 2027_20261008.zip (data.cms.gov dataset ed1496ea-23e7-41f1-9292-172fa842ccfb): basic drugs formulary file + plan information file, both dated 20261031 inside the zip; downloaded and aggregated 2026-10-30. Medication RxCUI sets resolved through the NLM RxNav (RxNorm) API.

What you pay

A tier is not a price; what you pay depends on your plan, pharmacy, and benefit stage; Extra Help or Medicaid can lower it further.

Sources: CMS Plan Benefit Package + formulary data; CMS NADAC · Checked 2026-11-08

Coverage by plan and tier

Of the 5,495 Medicare drug plans we track for 2027, 5,357 list Ibandronate (Boniva and others) — 97.5% of plans. Most of those plans put it on Tier 2: 3,671 plans, 68.5% of the plans that list it. Other plans place it on Tier 1 (1,247 plans), Tier 3 (351 plans) or Tier 6 (68 plans). For example: Aetna Medicare Dual Extra (HMO D-SNP) puts it on Tier 1; Aetna Medicare Dual Extra Care (PPO D-SNP) puts it on Tier 1; Aetna Medicare Value Plus (PPO) puts it on Tier 1. You can compare these plans side by side on our Medicare Advantage hub. A tier is not a price. What you pay also depends on whether you have met your plan's deductible, whether the drug costs a flat copay or a share of the price, and whether you get Extra Help or Medicaid.

Read next

• Part D in 2027: The $700 Deductible, the $2,400 Cap, and the $35 Insulin Rule
• Extra Help in 2027: Lower Drug Copays and Who Qualifies
• Checking Medicare Savings Programs and Extra Help

Part D spending averages (2024)

Source: CMS Medicare Part D Spending by Drug (Drug Spending Dashboard), release RY26 P04 V10, data through 2024 (DSD_PTD_RY26_P04_V10_DY24_BGM.csv), downloaded 2026-10-30

Companies covering this drug

Part D and Medicare Advantage plan sponsors that list this drug on a formulary, 50 at a time.